Primex News International

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Moving Into an Unfurnished Home? Here Is Where to Start

    November 14, 2026

    Outstanding H1 FY27 Financial Results & Strategic Outlook

    November 14, 2026

    DEV Information Technology Reports Q2 FY27 Total Income of Rs. 63.07 Cr, Up 28 Percent YoY; H1 FY27 Total Income Reaches Rs. 107.72 Cr, Up 16 Percent YoY

    November 14, 2026
    Facebook Twitter Instagram
    Primex News International
    • Home
    Facebook Twitter Instagram
    Primex News International
    Home»Finance»Outstanding H1 FY27 Financial Results & Strategic Outlook
    Finance

    Outstanding H1 FY27 Financial Results & Strategic Outlook

    Mohit ReddyBy Mohit ReddyNovember 14, 2026No Comments5 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email

    A New Ambani Orgochem Is Taking Shape. Super Specialty Chemistry. Stronger Performance. A New Growth Trajectory.

    Mumbai (Maharashtra) [India], November 13: Ambani Orgochem Limited, a super-specialty chemicals company established in 1985, with a diverse portfolio spanning peroxide derivatives, salicylic acid and salicylates, metal octoates, and water based acrylic polymer emulsions and dispersions, announces its Unaudited Financial Results for H1 FY27.

    01. Consolidated H1 FY27 | Performance At A Glance

    The numbers will tell one part of the story. The platform tells the next.

    Particulars (In ₹ Lakhs) H1 FY27 H1 FY26 YoY %
    Net Revenue From Operation 17,122.12 11,055.94 54.87%
    EBITDA 1,131.92 791.57 43.00%
    Net Profit 345.04 19.07 1709.33%
    EPS (In ₹) 4.02 0.249 1514.46%

    “Our strategic direction is to move beyond scale alone towards stronger value creation. This half-yearly performance is a testament to our operational focus on expanding our super-specialty chemicals portfolio. The emulsion expansion, salicylate development pipeline, addition of peroxide molecules and selective backward integration are interconnected initiatives driven by one objective: building a resilient portfolio with broader applications and a stronger technical foundation. Disciplined execution and customer validation will remain central to translating these developments into sustainable business outcomes.”
    ~ Mr. Aashay R. Shah, Strategy Director, Ambani Orgochem Limited

    02. The Strategic Shift

    From price-driven competition to value-driven chemistry

    The transformation is not simply a change in product mix. It is a move towards a chemistry platform where specialised products, process know-how, application understanding and manufacturing consistency increasingly work together. The Company’s current roadmap connects near-term capacity additions with a wider pipeline of molecules and derivatives, laying the groundwork for a portfolio built around more than volume alone.

    The Operating Thesis

    Specialised Chemistry + Technical Capability + Application Knowledge + Manufacturing Consistency

    03. Four Platforms. One Evolving Chemistry Story.

    Acrylic Waterborne Emulsions

    From Traditional Emulsions to Next-Generation Waterborne Chemistry

    Ambani Orgochem is rapidly growing and expanding it’s specialty acrylic waterborne emulsions divisions, targeting applications across paints, coatings, adhesives, carpets, construction, textiles and paper.

    Capacity Expansion

    ~2,000 T/month → ~4,500 T/month | 2.25x planned capacity

    The ongoing Tarapur MIDC expansion aims to strengthen manufacturing scale and support applications including waterproofing, pressure-sensitive adhesives, carpet binders and road infrastructure amongst others.

    STRATEGIC FOCUS | Scaling capacity. Advancing formulations. Unlocking application-led opportunities.

    Salicylic Acid & Derivatives

    Beyond the Core Molecule. Into Higher-Value Chemistry.

    Building on its in-house salicylic acid manufacturing capability, Ambani Orgochem is expanding into value-added derivatives for potential applications in cosmetics, fragrance, personal care, pharmaceuticals, and specialty chemicals.

    Capacity Roadmap

    • ~40 → ~200 T/month
    • Planned 5 x expansion

    Development Pipeline

    • 12+ salicylate molecules
    • Selected molecules progressing towards plant trials

    The identified pipeline includes octyl, 2-ethylhexyl, cyclohexyl, amyl, benzyl, isopropyl, hexyl, heptyl, homo-menthyl, sakura, iso-amyl and iso-butyl salicylates.

    STRATEGIC FOCUS | Moving downstream. Broadening the molecule portfolio. Pursuing higher-value opportunities.

    Peroxide Derivatives

    Expanding the Molecule Playbook—and Strengthening the Input Chain

    With 20+ existing products, specialised manufacturing infrastructure and in-house R&D, Ambani Orgochem is expanding its peroxide portfolio for polymer processing, composites, rubber, elastomers and other industrial applications.

    Product Innovation

    • 5 additional peroxide molecules under development

    Backward Integration

    • 2 critical raw materials under in-house development

    The Company has developed di-tert-amyl peroxide (DTA) through in-house R&D. Pilot trials for the two raw materials are nearing completion; these inputs could potentially support ~6 additional peroxide molecules, subject to validation and commercial assessment.

    STRATEGIC FOCUS | Expanding molecular capabilities. Securing critical inputs. Building a more resilient platform.

    Metal Octoates

    Established Chemistry. Expanding Industrial Relevance.

    Ambani Orgochem’s cobalt, zirconium and calcium octoates serve coatings, composites, printing and woodcare applications, including paint driers, FRP accelerators, inks and wood preservation.

    The Company is focused on product innovation, deeper industrial engagement and expanding global reach—reinforcing its application-led specialty chemistry offering.

    STRATEGIC FOCUS | Deepening product expertise. Expanding market reach. Strengthening application-led differentiation.

    04. Management Perspective

    Turning capability into value

    “The next chapter for Ambani Orgochem is about converting years of preparation into a more differentiated chemistry platform. On a consolidated basis, H1 FY27 reflects encouraging business momentum, with Net Revenue from Operations rising 54.87% YoY to ₹171.22 crore, EBITDA increasing 43.00% to ₹11.32 crore, and Net Profit surging 1,709.33% to ₹3.45 crore. EPS also rose 1,514.46% YoY to ₹4.02, reflecting a significant improvement over the corresponding period last year.

    Across our businesses, we are working to deepen product capabilities, expand downstream opportunities and strengthen the technical and manufacturing foundations behind our offerings. Our focus is on building chemistry that is harder to replicate, where application understanding, process discipline and consistent quality matter alongside the molecule itself.”
    ~ Mr. Rakesh H. Shah, Managing Director, Ambani Orgochem Limited

    “The past few years were about building the foundation. The next phase is about converting that foundation into value.”

    About Ambani Orgochem Limited

    Ambani Orgochem Limited, incorporated in 1985, is a super-specialty chemicals-focused company engaged in the manufacturing, processing, importing, supplying and exporting of high-performance Peroxide Derivatives, Salicylic Acid & Salicylates, Metal Octoates, and Eco-Friendly Acrylic Coatings & Adhesives.

    With over four decades of experience, the Company serves domestic & international markets with high-performance, environmentally friendly solutions aligned with sustainable development goals.

    Disclaimer/Forward-Looking Statements: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

    Finance
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Mohit Reddy
    • Website

    Related Posts

    Fairfax COO says IDBI has potential to be finest universal Indian bank with global reach

    November 13, 2026

    Davangere Sugar Q2 FY27 Net Profit Jumps 35% to Rs 3.54 Crore; Revenue Surges 49% to Rs 71.61 Crore

    November 13, 2026

    Park Medi World Q2 FY27 Revenue Jumps 25% to Rs 511 Crore; Hospital Capacity Expands 32%

    November 13, 2026

    Magellanic Cloud Announces Readiness of UAV Facility Premises (Counter-Drone) Under Joint Venture; Phased Operational Rollout Planned

    November 12, 2026

    Intense Technologies Announces H1 FY27 Results; Expands Client Portfolio and Strengthens BFSI Presence

    November 12, 2026

    Orient Green Power clocks Rs 106 Cr H1 FY27 Net Profit with an industry-leading 76% EBITDA margin

    November 12, 2026

    Comments are closed.

    Top Reviews
    Editors Picks

    Moving Into an Unfurnished Home? Here Is Where to Start

    November 14, 2026

    Outstanding H1 FY27 Financial Results & Strategic Outlook

    November 14, 2026

    DEV Information Technology Reports Q2 FY27 Total Income of Rs. 63.07 Cr, Up 28 Percent YoY; H1 FY27 Total Income Reaches Rs. 107.72 Cr, Up 16 Percent YoY

    November 14, 2026

    National Newborn Week 2026: Nutribray Calls for Stronger Newborn Care to Give Every Baby a Healthy Start

    November 14, 2026
    About Us
    About Us
    Our Picks

    Moving Into an Unfurnished Home? Here Is Where to Start

    November 14, 2026

    Outstanding H1 FY27 Financial Results & Strategic Outlook

    November 14, 2026

    DEV Information Technology Reports Q2 FY27 Total Income of Rs. 63.07 Cr, Up 28 Percent YoY; H1 FY27 Total Income Reaches Rs. 107.72 Cr, Up 16 Percent YoY

    November 14, 2026
    Top Reviews
    © 2026 Primex News International. Designed by Primex Media Services.
    • Home

    Type above and press Enter to search. Press Esc to cancel.